Drug Profile
Margetuximab - MacroGenics
Alternative Names: Anti-HER2-monoclonal-antibody-Green-Cross; MARGENZA; Margetuximab-cmkb; MGAH-22Latest Information Update: 03 Apr 2023
Price :
$50
*
At a glance
- Originator Raven biotechnologies
- Developer GC Biopharma; Green Cross; MacroGenics; Merck Sharp & Dohme; ZAI Lab
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HER2 positive breast cancer
- Phase II/III Gastric cancer; Oesophageal cancer
- Phase I Haematological malignancies; Solid tumours
- Discontinued Bladder cancer; Non-small cell lung cancer; Ovarian cancer
Most Recent Events
- 03 Apr 2023 Margetuximab is still in phase I trials for Solid tumors (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA, Bulgaria, Australia, Hong Kong, Poland, Spain, Thailand, Ukraine (IV) (NCT03219268)
- 03 Apr 2023 Margetuximab is still in phase I trials for Haematological-malignancies(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA, Bulgaria, Australia, Hong Kong, Poland, Spain, Thailand, Ukraine (IV) (NCT03219268)
- 27 Mar 2023 MacroGenics completes phase I trial for Haematological malignancies and Solid tumors (Combination therapy, Late stage disease, Metastatic disease, Inoperable/Unresectable) in USA, Australia, Bulgaria, Hong Kong, Poland, Spain, Thailand, Ukraine (NCT03219268)